open source pharma: the future of drug development
DESCRIPTION
Presented by Tomasz Sablinski at the Open Source Pharma Conference in July 2014 at Rockefeller Foundation Bellagio Center. Tomasz Sablinski's bio: http://www.opensourcepharma.net/participants/tomasz-sablinski Conference agenda: http://www.opensourcepharma.net/agenda.htmlTRANSCRIPT
July 2014
Open Innovation:The Future of Drug Development
Tomasz Sablinski, MDCo- Founder, CEO
“Toward a New, Open Source Pharmaceutical Industry”July 16, 2014 Bellagio, Italy#opensourcepharma
Does TLS Model Apply to Global Health ?
1. transparency
2. crowdsourcing
3. telemonitoring
Sixty Years of Declining Productivity
Dismal Success Rate in Late Development
The World of Computing Power vs. Pharma
The world ofPharma:CRF Books
Technology Today
most clinical studies are conducted as if we were still in the 1980s
yet
technologies exist to move clinical research into the 21st century
Technology Today
The first electronic medical record system was installed at Akron Children Hospital in 1962
February 17, 2012
Drug Development – Current Model
Multiple Patient Visitsto Expensive Sites
High-Cost Patient Recruitment
Insular Protocol DesignDriven by Market Access
+
20th Century Data Capture & Analyses
+ =
+
Pharma CompanyInfrastructure
+
Exorbitant Wasted Costs
Does This Look Familiar?
After: Henry Chesbrough, 2007
The closed innovation paradigm
The Open Innovation Paradigm
Open Innovation…
…Connecting Problems with Solutions
From Open Innovation to Crowdsourcing
one-on-one cooperations
crowdsourcing
consortia
Transparency Life Sciences
Transparency Life Sciences is the world’s first drug development company based on open innovation
We are revolutionizing drug developmentby transforming clinical trials – the most expensive & inefficient element
Drug Development – TLS Model
Get protocol input fromglobal community of patients, MDs,
researchers; facilitates patient recruitment
Minimize site visits,Improve data quality,Execute at fraction of
usual cost
+ =
Deliver more drugswith optimal labels
1. Crowdsourcing 2. Telemonitoring/eHealth
Impact
3. Transparency – Build trust & participation
Crowdsourcing – “10,000 Minds Are Better than 10”
Context• Web-based approach solicits global
input from researchers, patients, MDs
• Applies proven open innovation methodologies to clinical protocol design
• Opportunity to gain from expertise in and outside drug development
• Tiered incentives to participate:• Professional development (researchers)
• Impact / Belonging (patients)
• Community, financial (everyone)
Impact• More relevant protocols, lower costs,
patient and researcher engagement
TLS Crowdsourcing Stats – As of July, 2014
Visits: over 34,000Unique visitors: 21,8000
Registered users: 1,100 +Contributors: 370 +
TLS Protocol Builder – Sample Feedback
Protocol Builder (MS)
“Real advances in one's ability to walk, use hands, reduction in stiffness are key endpoints that I would like to see in studies.”
- Patient X
Crowd Input - Patients
“Metabolic response from Phase II would be required and useful for Phase III response ranges “
- Researcher Y
Crowd Input - Researchers
TLS Platform in Action – Metformin in Prostate Cancer
TLS Protocol Builder – Sample Researcher Feedback
The Long Tail Model, Chris Anderson - 2004
think of: Amazon or Netflix vs. brick and mortar retailers
The Long Tail Model in Clinical Research
design: KOLs only
participation: few easily accessible patients
I G N O R E D
The Long Tail Model – Transparency LS
design: patients and physicians involved; head or long tail
execution of clinical trials: making it possible for the long tail patients to participate: telemedicine
Growth of Telemedicine
The Wireless Revolution Hits Medicine
Telemonitoring – Riding the Wave
Context• Remote patient-monitoring device market
will reach $1.9 billion in 2014 (Juniper Research)
• By 2020, 160 million Americans will be monitored and treated remotely for chronic conditions (Nerac)
Impact• Goal: slash costs, improve quality
• Circumvent high fixed costs of hospitals, clinics (cost)• Eliminate observer bias (quality)
• Baseline assumption is first/last visit in clinic, balance of data collection via telemonitoring
• TLS leverages expanding ecosystem of FDA-compliant telemonitoring service providers
Benefits of Telemonitoring in Clinical Research
Quantitative
Obvious – less expensive trials
Qualitative
Non-obvious – new endpoints, novel designs
Three Reasons to be Optimistic
1. social changes / culture
2. technology
3. crisis
TLS Model Does Apply to Global Health
1. transparency
- essential to do good
2. crowdsourcing
- motivated contributors
3. telemonitoring
- cost efficiency, operational facility